Nitto Denko Corporation: New Anti-Fibrosis Drug With Molecular Targeting DDS Starts Phase-1B Dosing For Cirrhosis Patients

OSAKA, Japan--(BUSINESS WIRE)--Nitto Denko Corporation (Nitto) (TOKYO:6988)(ISIN:JP3684000007) announces the initiation of a phase-1b clinical study in the US started on September 2014, to administer a new anti-fibrosis drug in patients for the assessment of safety and efficacy.

Nitto has been developing an RNAi based drug for treating fibrosis in the liver and other organs since 2008 in collaboration with Sapporo Medical University and Hokkaido University. In March 2014, a Phase-1 clinical study in healthy volunteers was completed and no remarkable adverse events were observed, even at the highest dose tested. After thorough analysis of the data, the study results were summarized in a Clinical Study Report which concluded that the drug was safe and well tolerated. These results served as the basis of the phase-1b clinical study plan.

Help employers find you! Check out all the jobs and post your resume.

Back to news